Electrochemical detection of fluoroquinolone antibiotics in milk using a magneto immunosensor by Pinacho, Daniel G. et al.
Sensors 2014, 14, 15965-15980; doi:10.3390/s140915965 
 
sensors 
ISSN 1424-8220 
www.mdpi.com/journal/sensors 
Article 
Electrochemical Detection of Fluoroquinolone Antibiotics in 
Milk Using a Magneto Immunosensor 
Daniel G. Pinacho 1, Francisco Sánchez-Baeza 1,†, María-Isabel Pividori 2 and  
María-Pilar Marco 1,* 
1 Nanobiotechnology for Diagnostics Group (Nb4D), IQAC-CSIC and CIBER de Bioingeniería, 
Biotemateriales y Nanomedicina, c/ Jordi Girona 18-26, 08034 Barcelona, Spain;  
E-Mails: daniel.gonzalez@iqac.csic.es (D.G.P.); francisco.sanchez@iqac.csic.es (F.S.-B.) 
2 Sensors & Biosensors Group, Autonomous University of Barcelona (UAB), 08013 Bellaterra, 
Barcelona, Spain; E-Mail: Isabel.Pividori@uab.cat 
* Author to whom correspondence should be addressed; E-Mail: pilar.marco@iqac.csic.es;  
Tel.: +34-934-006-100; Fax: +34-932-045-904. 
† This work is dedicated to the memory of Dr. Francisco Sánchez-Baeza. 
Received: 24 May 2014; in revised form: 4 August 2014 / Accepted: 25 August 2014 /  
Published: 28 August 2014 
 
Abstract: An amperometric magneto-immunosensor (AMIS) for the detection of residues 
of fluoroquinolone antibiotics in milk samples is described for the first time. The 
immunosensor presented combines magnetic beads biomodified with an antibody with a 
broad recognition profile of fluoroquinolones, a haptenized enzyme and a magnetic 
graphite–epoxy composite (m-GEC) electrode. After the immunochemical reaction with 
specific enzyme tracer, the antibody biomodified magnetic beads are easily captured by an 
electrode made of graphite-epoxy composite containing a magnet, which also acts as 
transducer for the electrochemical detection. In spite of the complexity of milk, the use of 
magnetic beads allows elimination of potential interferences caused by the matrix 
components; hence the AMIS could perform quantitative measurements, directly in these 
samples, without any additional sample cleanup or extraction step. The immunosensor is 
able to detect up to seven different fluoroquinolones far below the MRLs defined by the 
UE for milk; for example ciprofloxacin is detected directly in milk with an IC50 of 0.74 µg/L 
and a LOD of 0.009 µg/L. This strategy offers great promise for rapid, simple,  
cost-effective, and on-site analysis fluoroquinolones in complex samples. 
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1. Introduction 
In modern intensive farming systems, the introduction of veterinary pharmaceuticals, pesticides and 
complex animal feeds has been critical to enhance the productivity by increasing the density of animals 
in the farms. In this sense, antibiotics are used for therapy, prevention and control of diseases, as well 
as growth promoters. The use of antibiotics is a determinant factor in the selection of resistance in 
bacteria and the dosage of antimicrobials is closely related to the rate of antimicrobial resistance 
developed in bacteria [1–3]. Development of resistance in zoonotic bacteria constitutes a public health 
concern, primarily due to the increased risk of treatments failure of human diseases. Food animals and 
foodstuffs are traded worldwide, thus, the occurrence of antimicrobial resistance is a worldwide problem. 
Fluoroquinolones (FQs) are synthetic antibiotics with a broad spectrum of antimicrobial activity 
that have been extensively used in veterinary medicine to treat or prevent bacterial infections in  
food-producing animals, aquaculture, and also pets. Several FQs are available for therapy of animals in 
many countries; however, the usage of these antibiotics differs greatly as regards animal species, 
indications, label indications, and geographic spread [4]. Because of the concerns regarding drug 
residues entering the food chain and contaminating environment, and consequently contributing to 
bacterial resistance development, maximum residue levels (MRLs) for the detection of FQ in several 
matrices from diverse animal species have been established by the European Commission (Council 
regulation 2377/90/EC [5] and council directive 96/23/EC [6]), as well as the requirements of the 
analytical methods that public health control and veterinary laboratories should use for this purpose 
(Commission decision 2002/657/EC [7]). In order to fulfill these requirements, and with the aim to 
protect the public health, official laboratories should be able to efficiently process a high number of 
samples at a low cost. The most employed analytical methods for the determination of FQs antibiotics 
in foods of animal origin are high-performance liquid chromatography (HPLC) coupled to 
fluorescence, mass spectrometric and ultraviolet detection [8–10]. These methods are considered as 
“gold standard” and they are used as routine in many laboratories. However, the expensive equipment 
required and the need for sample treatment limits their implementation in some settings. Although they 
are very suitable for confirmation, their use for screening purposes of large numbers of test samples 
become expensive. As a consequence, development of rapid, inexpensive and sensitive high sample 
throughput or on-site analytical strategies would be desirable. 
Antibodies based assays can provide the necessary reliability, low cost of the analysis/sample, ease 
of use, selectivity, and detectability to analyze small organic molecules. Moreover, the use of magnetic 
beads improves performance of the immunochemical reaction, due to an increase in the surface area, as 
well as achieving faster assay kinetics. Despite this increased surface area, matrix effect can be 
minimized due to their properties, as well as the improved washing and separation steps [11,12].  
On the other hand, electrochemical sensors have several advantages, such as their simplicity, 
portability, and low cost, giving them attractive sensing characteristics for their use as alternative 
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analytical methods, with accurate and fast responses without sample pre-treatment, opening up the 
possibility of direct on-site analysis with intuitive devices [13]. In this sense, electrochemical 
immunosensors combine the high sensitivity of the electrochemical transducers with the high 
selectivity of antibodies, thus, becoming powerful analytical tools for the detection of antibiotic 
residues [14,15]. Recently, Conzuelo et al. have been developed an immunosensor for the detection of 
tetracyclines antibiotics in milk using magnetic beads. In this case, they used a homemade magnet 
holder block to capture the magnetic beads onto a disposable commercial screen-printed electrodes, 
achieving good detectability in milk diluted two times in buffer [16]. 
In this paper an amperometric magneto-immunosensor (AMIS) based on the use of specific 
antibody biomodified magnetic beads, which can be captured by a magnetic graphite–epoxy composite 
(m-GEC) electrode is presented as a rapid, sensitive, simple, inexpensive, and user-friendly analytical 
method for the detection of fluoroquinolone antibiotics in milk. The device uses and enzyme tracer to 
generate electrochemical species and shows a broad selectivity profile for this antibiotic family. 
Fluoroquinolone residues can be directly detected in milk samples, without the need of previous 
cleanup or purification steps. 
2. Experimental Section 
2.1. Materials and Instruments 
Amperometric measurements were performed with a VersaSTAT 3 potentiostat (Princeton Applied 
Research, TN, USA). A three-electrode setup was used comprising a XM120 8 mm platinum plate 
auxiliary electrode (Radiometer Analytical SAS, France), double junction Ag/AgCl reference electrode 
(Orion 900200) with 0.1 M KCl as the external reference solution and a working electrode (magnetic 
graphite–epoxy composite (m-GEC)). The m-GEC was prepared using graphite powder with a particle 
size of 50 μm (BDH, UK) and Epo-Tek H77 (epoxy resin from Epoxy Technology, USA). 
Tosylactivated magnetic beads (Dynabeads® M-280 Tosylactivated) were purchased from Invitrogen 
Dynal AS (Oslo, Norway). Polystyrene microtiter plates were purchased from Nunc (Maxisorb, 
Roskilde, DK). Washing steps in ELISA were carried out using a SLT 96PW microplate washer (SLT 
Labinstruments GmbH, Salzburg, Austria). The electrochemical measurements performed were 
analyzed using VersaStudio software (Princeton Applied Research, TN, USA). To perform the optical 
measurements a SpectramaxPlus microplate reader (Molecular Devices, Sunnyvale, CA, USA) was 
used. The calibration curves were fitted to a four-parameter logistic equation using the Graph Prism 
software (GraphPad Software, San Diego, CA, USA). The magnetic separation during the washing 
steps was performed using a magnetic separator Dynal MPC-S (Dynal Biotech ASA, Norway) or  
96-Well Plate Separation Rack (Cortex Biochem, CA, USA). The pH and conductivity of all buffers 
and solutions were measured with a pH meter pH 540 GLP and a conductimeter LF 340, respectively 
(WTW, Weilheim, Germany).  
2.2. Chemicals and Immunochemicals 
The immunoreagents used in this study (Ab171 and 11-BSA), as well as the fluoroquinolone hapten 
11 were produced as previously described [17]. Ab171 was used as a pure IgG fraction of the 
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corresponding antisera (As171) and it was obtained by ammonium sulfate precipitation [18] followed 
by affinity chromatography purification (HiTrap Protein A HP, 1 mL, Amersham Biosciences, UK). 
Horseradish peroxidase (HRP) and bovine serum albumin (BSA) were purchased from Sigma  
(St. Louis, MI, USA). Ciprofloxacin was kindly provided by UQUIFA S.A (Lliça de Vall, Spain). The 
other fluoroquinolones used for crossreactivity studies were acquired from Aldrich Chemical Co. 
(Milwaukee, WI, USA). All the other chemical reagents used for the preparation of the bioconjugates, 
the biomodification of magnetic beads and the purification of the antibodies were of the highest 
available grade and were purchased from Fluka-Sigma-Aldrich (St. Louis, MO, USA) or Merck 
(Darmstadt, Germany). Stock solutions of different fluoroquinolones (0.01 M) were prepared in 0.05 M 
NaOH solution and stored at 4 °C for one month. 
2.3. Buffers and Solutions 
Phosphate-buffered saline (PBS) is 0.01 M phosphate buffer on a 0.8% saline solution, and  
the pH is 7.5. PBST is PBS with 0.05% Tween 20. PBSTCa is PBST with 1 mM calcium chloride. 
Coating buffer is 0.05 M carbonate-bicarbonate buffer, pH 9.6. Citrate buffer is a 0.04 M solution of 
sodium citrate, pH 5.5. The substrate solution for optical measurements contains 0.01% TMB 
(3,3',5,5'-tetramethylbenzidine) and 0.004% H2O2 in citrate buffer. For electrochemical measurements, 
PBSE (0.1 M phosphate buffer, with 0.1 M KCl, pH 7) was used. During biomodification  
of the magnetic beads, PBS containing 0.1% (w/v) BSA (PBSBSA), and 0.2 M 
tris(hydroxymethyl)aminomethane (Tris), pH 8.5 containing 0.1% (w/v) BSA (TrisBSA) were used.  
All buffer solutions were prepared with ultrapure water (UPW, D11971 Barnstead). 
2.4. Construction of Magneto Graphite–Epoxy Composite (m-GEC) Electrodes 
The magnetic graphite–epoxy composite (m-GEC) electrodes were constructed following the 
protocol previously reported for electrochemical immunosensing [19–21]. Briefly, epoxy resin and 
graphite powder were hand-mixed in a 1:4 (w/w) ratio. Then, a cylindrical PVC sleeve body (6 mm i.d.), 
with a copper plate as electrical contact, was filled with the resulting paste and a small neodymium 
magnet (3 mm i.d.) was placed into the center of this electrode. After that, tightly packed the GEC 
paste in the electrode body gap, the m-GEC electrodes were cured at 40 °C for 1 week to obtain a rigid 
composite. Before each measurement, the electrode surface was renewed by a simple polishing 
procedure, wetted with UPW, and then thoroughly smoothed with abrasive paper. 
2.5. Preparation of the Enzyme Labeled Immunoreagents 
HRP was covalently coupled to Ab171 and fluoroquinolone hapten 11 through a two steps 
procedure, previously described by Abuknesha [22], with modifications. 
Step 1: Activation of HRP. A solution of HRP (9 mg, 0.225 μmol) in coating buffer (1.8 mL) was 
added to cyanuric chloride (900 μg, 4.9 μmol) and the mixture was stirred during two hours at room 
temperature (RT). Afterwards, the mixture was dialyzed (4 × 0.5 mM PBS and 1 × UPW) and finally 
freeze-dried to obtain 8.02 mg of HRPCC (89% of yield). 
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Step 2: Bioconjugation. A solution of Ab171 (1.8 mg, 0.012 µmol) in coating buffer (250 µL) and a 
solution of hapten 11 (0.6 mg, 1.95 µmol) in DMF (60 µL) were added to a two solutions of HRPCC  
(3 mg, 0.07 μmol) in coating buffer (500 and 690 µL respectively) and the mixtures were stirred for 4 h 
at 37 °C. After that, the mixture of the enzyme labeled antibody was purified by 40% (NH4)2SO4 
precipitation [18] and the precipitate was restored with PBS, pH 7.5. Finally, the solutions of enzyme 
labeled antibody and enzyme tracer were dialyzed (4 × 0.5 mM PBS and 1 × UPW) and freeze-dried to 
obtain 1.23 mg of Ab171-HRP (53% of yield) and 2.11 mg of 11-HRP (70% of yield). All 
immunoreagents were stored at −80 °C and unless otherwise indicated, working aliquots were stored at 
4 °C in PBS at 1 mg/mL. 
2.6. Preparation of the Biomodified Magnetic Beads 
The 11-BSA bioconjugate and the previously purified Ab171 were covalently coupled to MB-Tosyl 
magnetic beads to obtain the corresponding modified magnetic beads 11-BSA-MB and Ab171-MB. 
According to the manufacturer specifications, covalently biomodified magnetic beads can be stored at 
4 °C for a minimum of three months without a loss of activity. A volume of 350 µL (30 mg/mL,  
0.1–0.2 mmol/g) of tosyl-modified magnetic beads (10.5 mg), were washed twice with 1 mL of coating 
buffer, avoiding foaming. After that, the magnetic beads were suspended in coating buffer (850 µL) 
and a solution of either 11-BSA or Ab171 (1 mg/mL, 150 µL) was then added. The magnetic beads 
were incubated 48 h at RT with a slow orbital rotation in order to avoid bead sedimentation. The 
modified beads were then washed twice in PBSBSA for 5 min at 4 °C and with TrisBSA for 24 h at RT 
with slow orbital rotation and washed again with PBSBSA for 5 min at 4 °C. Finally, the magnetic 
beads were resuspended in PBSBSA to reach a 15 mg/mL stock solution and were stored at 4 °C. The 
yield of the coupling was evaluated by means of a UV test (δ = 280 nm), in which the protein 
concentration in the supernatant was analyzed before and after the bioreaction. The biomodification 
yield, calculated as described above, was 82.5 ± 1% for 11-BSA-MB and 92 ± 2% for Ab171-MB. 
2.7. ELISA and m(magneto)-ELISA Protocol 
ELISA. Two different competitive formats were assessed in this study, coating antigen format (CAf) 
comprising the immunoreagents Ab171-HRP and 11-BSA and enzyme tracer format (ETf) comprising 
the reagents 11-HRP and As171. 
Microtiter plates were coated with 11-BSA (0.5 μg/mL, 100 μL/well) and As171 (8000 times 
diluted, 100 μL/well) for CAf and ETf, respectively, both of them in coating buffer at RT for 4 h and 
covered with adhesive plate sealers. Then, the plates were washed with PBST (four times,  
300 μL/well) and ciprofloxacin standard solutions (from 0.01 nM to 10,000 nM, in PBSTCa, 50 μL/well) 
were added to the microtiter plates, followed by the addition of Ab171-HRP (0.25 μg/mL in PBSTCa, 
50 μL/well) and 11-HRP (0.25 μg/mL in PBSTCa, 50 μL/well) for CAf and ETf respectively. After  
30 min, the plates were washed again, and the substrate solution was added (100 μL/well). Color 
development was stopped after 30 min at RT with 2 M H2SO4 (50 μL/well), and the absorbances were 
read at 450 nm. 
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m-ELISA. Two different competitive formats were assessed in this study, magneto coating antigen 
format (m-CAf) comprising the immunoreagents Ab171-HRP and 11-BSA-MB and magneto enzyme 
tracer format (m-ETf) comprising the reagents 11-HRP and Ab171-MB. 
Ciprofloxacin standard solutions in PBSTCa (50 µL, from 0.01 to 10,000 nM) were mixed with a 
suspension of the biomodified magnetic beads (50 µL, 0.3 mg/mL of 11-BSA-MB for m-CAf and 
0.125 mg/mL of Ab171-MB for m-ETf) followed by the addition of the enzyme labeled 
immunoreagent solutions (50 µL, 0.5 µg/mL of Ab171-HRP for m-CAf and 0.25 µg/mL of 11-HRP for 
m-ETf). The competitive immunological reaction was allowed to proceed for 30 min at RT vigorously 
shaking. The magnetic beads were then washed with PBST (150 µL, three times) and the substrate 
solution (100 µL) was added and incubated again for 30 min at RT. The enzymatic reaction was 
stopped by adding 2 M H2SO4 (50 µL). Finally, the supernatants were removed from the magnetic 
beads and then added to a different plate for measuring the absorbance at 450 nm. 
In both cases (ELISA and m-ELISA), the standard curve was fitted to a four-parameter logistic 
equation according to the formula y = (A − B)/[1 + (X/C) D] + B, where A is the maximal signal, B the 
minimum signal, C the concentration producing 50% of the maximal signal, and D is the slope at the 
inflection point of the sigmoid curve. LOD values were obtained as 90% of A value, the maximal signal. 
2.8. Specificity Studies 
Stock solutions of different fluoroquinolone antibiotics were prepared in 0.05 M NaOH at a 
concentration of 0.01 M. Standard solutions were prepared for each analyte in PBSTCa (from 0.01 nM 
to 10,000 nM) and measured using the ELISA and m-ELISA, as described above. For all 
fluoroquinolones it was possible to build standard curves that fitted to the four-parameter equation 
mentioned above. The cross-reactivity values were calculated according to the equation: (IC50 
Ciprofloxacin/IC50 tested compounds) × 100. 
2.9. Amperometric Magneto Immunosensor (AMIS) Procedure 
For electrochemical readout (AMIS), only the magneto enzyme tracer format (m-ETf), comprising 
the reagents 11-HRP and Ab171-MB, was assessed. A schematic representation of the whole 
procedure is shown in Figure 1. All the steps were performed in 5 mL polypropylene tubes, and all the 
referred quantities in this protocol are the amount added per tube. After the incubation or washing 
steps, the magnetic beads were separated from the supernatant using a magnetic separation rack until 
the beads migrated to the sides of the tube and the liquid was clear (approximately 1 min). 
Ciprofloxacin standard solutions (50 µL, from 0.01 to 10,000 nM in PBSTCa) were placed in the 
polypropylene tubes and mixed with the Ab171-MB suspension (50 µL, 0.25 mg/mL in PBSTCa) and 
the solution of 11-HRP (50 µL, 0.5 µg/mL in PBSTCa), in this specific order, and incubated for 30 min 
at RT with gentle stirring. Afterwards, the magnetic beads were washed with PBST (3 × 300 μL), 
resuspended in PBST (160 μL) and captured by dipping the m-GEC electrode into the solution in the 
tubes just before the amperometric measurement in order to prevent undesired desorption of the 
protein complexes (see Figure 1). The magnetic beads-modified m-GEC was used as a working 
electrode to determine the amperometric signal by dipping the three-electrode setup in 20 mL of PBSE. 
The electrochemical signal was recorded after the addition of the mediator (hydroquinone, HQ;  
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1.81 mM) and the enzyme substrate (hydrogen peroxide, 1.11 mM). The response was determined by 
polarizing the working electrode surface (m-GEC) at −0.150 V. As well as for ELISA and m-ELISA, 
the standard curve was fitted to a four-parameter logistic equation according to the formula (see above). 
Figure 1. Scheme of the AMIS procedure for fluoroquinolones. Firstly, ciprofloxacin 
standards, Ab171-MB suspension and 11-HRP solution were mixed and incubated for  
30 min with gentle stirring. After three washing steps using PBST buffer, performed with 
the aid of a magnetic rack, the modified magnetic beads are captured by the m-GEC. Then, 
the electrode is transported to the electrochemical cell using a three-electrode setup for the 
amperometric measurement. 
 
2.10. Milk Matrix Effect 
Bovine whole milk samples testing free of fluoroquinolones were provided by the Agencia 
Española para la Seguridad Alimentaria (AESA; Spanish Agency for Food Security). Different 
dilutions of whole bovine milk were employed for generate ciprofloxacin standard curves. The curves 
obtained using ELISA, m-ELISA and AMIS procedures were compared with the curve prepared in 
PBSTCa buffer in order to evaluate the matrix effect. 
3. Results and Discussion 
The AIMS presented here, is based on the use of an enzyme tracer, magnetic beads modified with 
antifluoroquinolone antibodies, and graphite–epoxy composite electrodes containing a magnet inside 
(m-GEC electrodes). The samples or standards of fluoroquinolones are mixed with the 
immunoreagents listed above, and after incubation, the immunocomplexes linked to the magnetic 
beads are separated from the free fraction of the enzyme tracer with the support of a magnetic rack and 
later on captured with the m-GEC (see Figure 1). The amperometric signal is determined by using the 
magnetic beads-modified m-GEC electrode as a working electrode in a three-electrode setup, recording 
the current intensity produced by the enzymatic reaction catalyzed by the HRP of the immunocomplex. 
The amperometric signal is related to the amount of enzyme tracer bound to the magnetic beads 
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captured by the electrode that is inversely proportional to the amount of analyte present in the sample. 
The enzyme oxidizes the substrate (H2O2 to H2O) at the same time that hydroquinone (HQ) is oxidized 
to quinone (Q), and subsequently reduced again by the electrode applied potential (see Figure 1). 
3.1. Preparation and Characterization of Enzyme Labeled Immunoreagents 
Recently, our group has developed generic antibodies against fluoroquinolones and an indirect 
competitive ELISA assay able to detect, at least, the most important fluoroquinolones used in the 
veterinary field with values of IC50 and LOD below the MRLs established by the UE for several  
tissues [17]. This ELISA format comprises a competition step between the coating antigen and the 
analyte for the antibody, and also implies a second step using a secondary anti-antibody labeled with 
an enzyme for the generation of the final signal. With the aim to avoid this second step, halving the 
analysis time, two new enzyme labeled immunoreagents were prepared and evaluated by ELISA. The 
first one was prepared by direct coupling of HRP to the antifluoroquinolone antibody (Ab171) and the 
second one by coupling the same enzyme to the fluoroquinolone hapten (11) that showed the best 
performance in the ELISA previously developed. 
For the preparation of the labeled specific antibody, two methodologies were employed. In a first 
approach the sugars of the antibodies were oxidized by sodium periodate, in order to obtain aldehyde 
functionalities able to react with the amines of the HRP [23]. In this case the enzyme labelled antibody 
obtained showed a high degree of non-specific absorption when it was characterized by ELISA assay 
(data don’t show), for this reason this strategy was discarded. In a second approach, cyanuric chloride 
was employed as crosslinker using the different reactivity of the chlorine atoms [22]. The most 
reactive chlorine moiety of the linker reacted, on a first step, with the amines of the HRP at RT. After 
purification of the activated HRP, the second reactive chlorine of the crosslinker was reacted with the 
amines of the lys residues of the antibody at 37 °C. In this case an enzyme labeled antibody  
(Ab171-HRP) showing very good performance in ELISA assay was obtained (see Figure 2 and Table 1). 
Thus, in the same way, an enzyme tracer (11-HRP) was prepared by the reaction of the amine group of 
the fluoroquinolone hapten 11 with the chlorine atom of the activated HRP a 37 °C. Both 
bioconjugates were tested by ELISA using distinct formats (CAf, coating antigen and ETf, enzyme 
tracer formats) The CAf ELISA assay, performed using plates coated with the competitor 11-BSA and 
Ab171-HRP in solution (see experimental Section 2.7), showed a very good detectability for 
ciprofloxacin with an IC50 of 0.84 µg/L and a LOD of 0.06 µg/L. The enzyme tracer was evaluated 
using an ETf ELISA, using plates coated with the antifluoroquinolones antisera (As171) without 
previous purification (see experimental Section 2.7). Again, a very good detectability was accomplished 
(see Figure 2 and Table 1), reaching an IC50 of 0.86 µg/L and a LOD of 0.09 µg/L for ciprofloxacin. 
The yield of the bioconjugation for 11-HRP (63%) was higher than for the Ab171-HRP (47%), 
maybe due to a minor purification steps involved during the process. Both ELISA formats show a very 
close detectability in terms of IC50 and LOD for ciprofloxacin, and similar to the previous ELISA 
developed (IC50 = 0.35 µg/L, LOD = 0.04 µg/L), demonstrating that there was no loss of activity after 
labeling of the specific antibody. On the other hand, the similarity found between both formats 
indicates that the assay is not dependent on the format. 
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Figure 2. ELISA calibration curves of the different ELISA formats using the 
immunoreagents produced (a) CAf in blue; (b) TEf in red. Each point was the average of at 
least three-well replicates, and the assays were run on two different days. 
 
Table 1. Features of the different ELISA formats using the immunoreagents produced. 
3.2. Preparation and Characterization of Biomodified Magnetic Beads 
The main advantages of the use of magnetic beads in electrochemical immunosensors are their easy 
manipulation, the increase in the surface area, faster assay kinetics, improved washing and separation 
steps, the possibility of renewing the surface of the electrode and perspectives for system automation 
and miniaturization [11,12]. In this sense, two types of biomodified magnetic beads were prepared 
using tosyl-activated magnetic beads, ones by covalent binding of the Ab171 and others by covalent 
binding of the coating antigen 11-BSA. The biomodified magnetic beads were characterized by  
m-ELISA and both types of beads show a very good performance in m-ELISA, keeping the 
detectability that the same immunoreagents showed in ELISA (see Figure 3 and Table 2). 
The yield of the biomodification was checked by testing the protein content from the supernatant 
before and after the bioconjugation using UV at 280 nm, by interpolation the value of supernatant into 
a calibration line built using the corresponding protein (Rabbit IgG and BSA). In both cases was higher 
than 80%.  
As in the case of ELISA, the m-ELISA parameters found were similar for both formats. Since 
production of 11-HRP was more cost and time effective, the TEf was selected to continue with the 
development of the AIMS, using the Ab171-MB. 
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Slope −0.808 −1.436 
Dynamic range (µg/L) 0.16–2.20 0.33–2.35 
LOD (µg/L) 0.060 0.086 
R2 0.9854 0.9945 
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Figure 3. m-ELISA calibration curves of the different ELISA formats using the 
immunoreagents produced and the biomodified magnetic beads. (a) CAf, in blue; (b) TEf, 
in red. Each point was the average of at least three-well replicates, and the assays were run 
on two different days. 
 
Table 2. Features of the different m-ELISA formats using the immunoreagents produced 
and the biomodified magnetic beads. 
Table 3. Values of IC50 and cross-reactivity percentage of related fluoroquinolone 
compounds in the ELISA and m-ELISA. 
ELISA m-ELISA MRL [24] 
IC50 [µg/L] %CR IC50 [µg/L] %CR In Milk [µg/L] 
Ciprofloxacin 0.93 100 1.31 100 100 
Enrofloxacin 1.23 82 2.04 66 100 
Danofloxacin 7.34 14 12.5 11 30 
Difloxacin 1.42 86 2.34 70 Banned 
Marbofloxacin 2.56 41 8.93 16 75 
Flumequine 1.94 39 4.82 22 50 
Oxolinic Acid 7.01 11 4.30 24 Banned 
3.3. Specificity Assay 
In order to prove that the generic pattern of fluoroquinolone recognition was maintained in the 
magneto amperometric immunosensor, the specifitity of the new immunoreagents was tested using the 
TEf. Calibration curves for fluoroquinolones regulated by the UE were built in PBSTCa buffer and were 
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 m-CAf (11-BSA-MB/Ab171-HCH) m-TEf (Ab171-MB/11-HCH) 
Amax 1.679 1.814 
Amin 0.081 0.052 
IC50 (µg/L) 0.88 ± 0.42 0.89 ± 0.41 
Slope −0.799 −0.901 
Dynamic range (µg/L) 0.15–5.47 0.10–3.73 
LOD (µg/L) 0.052 0.034 
R2 0.984 0.985 
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run using ELISA and m-ELISA. For both assays, the standard curves for all fluoroquinolones were 
fitted to the four-parameter equation mentioned above with very good correlation coefficients  
(≥0.985). Table 3 shows the values of IC50, cross reactivity percentage, with respect to the 
ciprofloxacin and the MRLs values, fixed by UE for milk. Detectability were very similar for both 
assays and close to the indirect ELISA previously reported [17], with a slight increase of IC50 for  
m-ELISA respect to the microplate-based ELISA except for the oxolinic acid. In all cases the IC50 
values were lower than 10 µg/L and seven fluoroquinolones congeners were recognized at 
concentrations below to the MRLs established by the UE in milk. 
Figure 4. Milk matrix effect using (a) ELISA and (b) m-ELISA for the TEf. Curves were 
built in (1) PBSTCa buffer, (2) Whole milk, (3) Whole milk diluted two times in PBSTCa 
buffer, (4) Whole milk diluted five times in PBSTCa buffer and (5) Whole milk diluted 10 
times in PBSTCa buffer. Each point was the average of at least three-well replicates, and the 
assays were run on two different days. 
 
3.4. Milk Matrix Effect 
The term matrix effect is defined as the combined effect of all components of the sample other than 
the analyte on the measurement of the quantity [25]. Milk is a complex matrix composed by thousands 
of compounds, including high contents of fat, protein, carbohydrates, and minerals [26], which can 
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affect the antibody recognition event. For this reason, the matrix effect was evaluated in whole milk 
free of fluoroquinolones by preparing standard curves of ciprofloxacin in milk, and milk diluted 
several times in PBSTCa buffer, and running them in ELISA and m-ELISA. The calibration curves 
obtained under such conditions were compared to that built in just PBSTCa buffer.  
In ELISA assay, the matrix effect observed consisted in a decrease of the 25% of the maximum 
absorbance when the calibration curve was built directly in whole milk, while the calibration curves 
built in milk diluted more than five times in buffer were parallel to the one built in buffer (see Figure 4). 
Despite the decrease in maximum absorbance, the IC50 remains constant with values of 0.87 µg/L for 
buffer and 0.92 µg/L for milk. Regarding m-ELISA assay, no matrix effect was observed, even in raw 
milk without any dilution. The calibration curves showed a perfect parallelism to the buffer curve  
(see Figure 4). The fact that the matrix effect was fully eliminated in m-ELISA reveals the advantages 
of using magnetic particles in the assay and suggests the possibility of directly analyzing whole milk 
samples with m-ELISA format without any kind of sample pretreatment, allowing us to keep a very 
good detectability. 
3.5. Amperometric Magneto Immunosensor 
Electrochemical readout for the implementation of the AMIS was addressed once the reagents 
(enzyme tracer and modified magnetic beads) were fully characterized by ELISA and m-ELISA. From 
two-dimensional experiments, optimum concentrations of Ab171-MB (0.25 mg/mL) and 11-HRP  
(0.5 µg/mL) were adjusted to obtain a final current of 7–10 µA after 30 min of immunochemical 
reaction in absence of analyte. Standard solutions of ciprofloxacin (from 0.01 to 10,000 nM in PBSTCa 
buffer) were mixed with the biomodified magnetic beads Ab171-MB and 11-HRP (see experimental 
Section 2.9), incubated for 30 min and, captured with the m-GEC. Measurement of the 
immunocomplexes formed was performed in the electrochemical cell. The detectability of the AMIS in 
buffer, in term of its IC50 recorded was 0.74 μg/L, while the LOD, in term of the IC80, was 0.02 μg/L 
(see Table 4). The same experiment was performed preparing the same standard solutions in undiluted 
whole milk to check if the matrix affected the electrochemical readout, obtaining and IC50 of 0.74 μg/L, 
while the LOD was 0.009 μg/L (see Table 4), which indicated that the results obtained by the m-ELISA 
could be reproduced also with the immunosensor. Figure 5 shows the curves generated, in buffer and 
in milk. demonstrating the absence of significant non specific interferences caused by the milk in the 
AMIS, as in the case of m-ELISA. Both calibration curves, the one prepared in buffer and the one 
prepared in milk are almost identical, opening the possibility to prepare the calibration curves in 
buffer. Moreover, since the LOD is much below of the MRL values established by the EC, the milk 
will have to be diluted with buffer in order to use the present immunosensor for screening purposes, 
reducing even more the probability to produce non specific interferences in the assay. 
Comparing the parameters obtained in m-ELISA and in AMIS, IC50 and LOD are quite similar, 
only the slope of the curve is lower in the case of AMIS. Thus, we can conclude that using the AMIS 
developed it is possible to analyze directly fluoroquinolone residues milk samples without any  
sample treatment.  
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Figure 5. Calibration curves for ciprofloxacin with electrochemical readout using AMIS. 
(a) In PBSTCa in red (b) In whole milk in green. Each point was the average of at least 
three-well replicates, and the assays were run on two different days. 
 
Table 4. Features of the amperometric magneto-immunosensor (AMIS) in PBSTCA buffer 
and whole milk samples using ciprofloxacin as standard. 
On the other hand, several samples can be simultaneously processed with the aid of magnetic racks. 
In this work, up to 24 samples have been measured at the same time in 4.5 h. 
4. Conclusions 
An electrochemical magneto-immunosensor for the detection of fluoroquinolone antibiotics in milk 
has been developed. Time of the analysis has been decreased at half by the use of two new enzyme 
labeled immunoreagents, prepared by covalent binding of antibody and hapten for fluoroquinolones to 
the enzyme HRP using cyanuric chloride as crosslinker. In addition, magnetic beads have been 
biofunctionalized using fluoroquinonole specific antibodies and antigen bioconjugates. All 
immunoreagents, including magnetic beads, have been characterized by ELISA and m-ELISA using 
two formats, ETf and CAf. The parameters extracted from this characterization indicate that 
detectability is not dependent on the format or type of assay. Studies of selectivity indicate that the 
immunoreagents developed are able to detect a significant number of the fluoroquinolone congeners 
regulated by UE with values of IC50 below 10 µg/L. The use of magnetic beads completely eliminates 
the matrix effect caused by milk due to improvement washing steps and better kinetic profile during 
the immunochemical reaction. Samples of milk can be directly analyzed without any sample treatment 
or dilution using AMIS approach and also using m-ELISA for high-throughput screening purposes, 
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Imax (µA) 9.916 8.641 
Imin (µA) 0.472 0.492 
IC50 (µg/L) 0.74 ± 0.50 0.74 ± 0.48 
Slope −0.532 −0.586 
Dynamic range (µg/L) 0.063–8.05 0.043–7.38 
LOD (µg/L) 0.017 0.009 
R2 0.980 0.981 
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both of them with excellent detection limits (LOD for ciprofloxacin 0.009 µg/L for AMIS and  
0.034 µg/L for m-ELISA). The simplicity of the electrochemical magneto immunosensor presented 
here makes it suitable for rapid and cheap semiquantitative and quantitative on-site analysis of 
fluoroquinolones in milk by nonqualified personnel.  
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